SAM Partner Michael Sherman Represents Xaleron Pharmaceuticals Against Actavis and Allergan

Stubbs Alderton & Markiles Partner Michael Sherman successfully represents Xaleron Pharmaceuticals against Actavis and Allergan Inc. in dispute over unfair competition in bringing to market a novel treatment for hay fever utilizing botulinum toxin.  Confidential monetary settlement one month before trial vindicated Xaleron’s claims.

Read the full article here. 

Stubbs Alderton & Markiles attorney representing Xaleron Pharmaceuticals is Michael A. Sherman.

For more information on our Business Litigation Practice, contact Michael A. Sherman at msherman@stubbsalderton.com.

FacebookTwitterGoogle+LinkedInEmail